Catch and Release Immunotoxins: CAR-Bombs for Cancer
Catch and Release Immunotoxins: CAR-Bombs for Cancer
批准号:
10062878
负责人:
Joseph P Balthasar
金额:
$36.42万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-12-07 至 2021-11-30
关键词:
AffinityAmerican Cancer SocietyAntibodiesBindingBiologicalCarcinoembryonic AntigenCell surfaceCellsCessation of lifeColorectal CancerCytoplasmDataDiagnosisDissociationDoseDrug KineticsEndosomesEvaluationExhibitsGALAHealthHumanImmunotoxinsIn VitroIncidenceIndividualInvestigationKineticsLiposomesMalignant NeoplasmsMembraneModelingMonoclonal AntibodiesMusOperative Surgical ProceduresPatternPeptidesPhysiologicalPlasmaPopulationProteinsRadiationRibosomesSafetySmall Interfering RNASumSystemTestingToxic effectToxinToxin ConjugatesTumor SuppressionUnited StatesWorkanaloganti-cancerantibody conjugateantigen bindingbasecancer cellcancer therapycancer typecellular targetingchemotherapycytotoxicityhuman modelimprovedin vivomacromoleculemembrane modelmouse modelneoplastic cellnovelpharmacokinetic modelreceptor bindingreceptor mediated endocytosistargeted deliverytumortumor growthtumor xenograftuptakevirtualvirtual delivery
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
The American Cancer Society estimates that in 2016 there will be 1.7 million new cancer cases diagnosed and
600,000 cancer deaths in the United States. Although advances have been made in the treatment of cancer
with surgery, radiation, chemotherapy, and with biologics, there is a critical need to develop novel treatment
approaches with promise for improved selectivity, potency, and efficacy. This project introduces a new and
previously untested platform strategy to enhance the efficiency of delivery of macromolecules to the cytoplasm
of targeted cells. The central component of the strategy is the use of “catch-and-release” monoclonal
antibodies (CAR), with pH-dependent receptor binding. The CAR antibodies are conjugated to highly potent
macromolecular toxins (CAR-toxin) and to endosome escape peptides (CAR-EEP). Combined administration
of CAR-toxin and CAR-EEP conjugates allows efficient, targeted delivery and release of the toxin in the
cytoplasm, enabling highly selective and potent anti-cancer efficacy. To pursue this project, we have
developed a novel catch-and-release anti-carcinoembryonic antigen (CEA) antibody (10H6), with high affinity
CEA binding at physiological pH, and with dramatically reduced binding at acidic pH. Preliminary data have
been generated to assess the binding, cytotoxicity, and pharmacokinetics of 10H6, which in sum, strongly
support the feasibility of the work. An interdisciplinary team has been assembled to evaluate this approach,
with three experimental aims that will: (1) examine and optimize the utility of catch and release conjugates for
cytoplasmic delivery of macromolecules to cancer cells in vitro, (2) test hypotheses regarding the tumor
selectivity of in vivo disposition of the antibody conjugates, and (3) evaluate the safety and efficacy of the
catch-and-release mAb conjugates in the treatment of mice bearing human xenograft tumors. The project, if
successful, will establish a new targeting concept, with potential utility in enhancing the efficiency of
cytoplasmic delivery of virtually any macromolecule to any type of cancer.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.3389/fphar.2022.837744
发表时间:
2022
期刊:
Frontiers in pharmacology
影响因子:
5.6
作者:
[Bordeau BM, Abuqayyas L, Nguyen TD, Chen P, Balthasar JP]
通讯作者:
Balthasar JP
DOI:
10.20892/j.issn.2095-3941.2020.0704
发表时间:
2021-08-15
期刊:
Cancer biology & medicine
影响因子:
5.5
作者:
[Bordeau BM, Balthasar JP]
通讯作者:
Balthasar JP
DOI:
10.1208/s12248-022-00698-x
发表时间:
2022-03-25
期刊:
The AAPS journal
影响因子:
--
作者:
[]
通讯作者:
DOI:
10.1158/1535-7163.mct-22-0192
发表时间:
2022-10-07
期刊:
Molecular cancer therapeutics
影响因子:
5.7
作者:
[]
通讯作者:
DOI:
10.1158/0008-5472.can-20-3822
发表时间:
2021-08-01
期刊:
Cancer research
影响因子:
11.2
作者:
[Bordeau BM, Yang Y, Balthasar JP]
通讯作者:
Balthasar JP
共 6 条
Pharmacokinetic / Pharmacodynamic Optimization of ADC Therapy for Acute Myeloid Leukemia
-
批准号:10561230
-
项目类别:
-
资助金额:$42.69万
-
财政年份:2023
-
负责人:Joseph P Balthasar
-
依托单位:
Enhancement of ADC selectivity by inverse targeting: Mechanistic studies and optimization
-
批准号:10415220
-
项目类别:
-
资助金额:$35.6万
-
财政年份:2021
-
负责人:Joseph P Balthasar
-
依托单位:
Enhancement of ADC selectivity by inverse targeting: Mechanistic studies and optimization
-
批准号:10312178
-
项目类别:
-
资助金额:$36.33万
-
财政年份:2021
-
负责人:Joseph P Balthasar
-
依托单位:
Enhancement of ADC selectivity by inverse targeting: Mechanistic studies and optimization
-
批准号:10623301
-
项目类别:
-
资助金额:$36.73万
-
财政年份:2021
-
负责人:Joseph P Balthasar
-
依托单位:
Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumors
-
批准号:10623152
-
项目类别:
-
资助金额:$35.59万
-
财政年份:2020
-
负责人:Joseph P Balthasar
-
依托单位:
Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumors
-
批准号:10164739
-
项目类别:
-
资助金额:$36.27万
-
财政年份:2020
-
负责人:Joseph P Balthasar
-
依托单位:
Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumors
-
批准号:10397091
-
项目类别:
-
资助金额:$35.54万
-
财政年份:2020
-
负责人:Joseph P Balthasar
-
依托单位:
Pharmacokinetic strategies to optimize IP chemotherapy
-
批准号:7144306
-
项目类别:
-
资助金额:$27.72万
-
财政年份:2006
-
负责人:Joseph P Balthasar
-
依托单位:
Pharmacokinetic strategies to optimize IP chemotherapy
-
批准号:7646274
-
项目类别:
-
资助金额:$25.6万
-
财政年份:2006
-
负责人:Joseph P Balthasar
-
依托单位:
Pharmacokinetic strategies to optimize IP chemotherapy
-
批准号:7286074
-
项目类别:
-
资助金额:$25.53万
-
财政年份:2006
-
负责人:Joseph P Balthasar
-
依托单位:
Pharmacokinetic strategies to optimize IP chemotherapy
-
批准号:7477278
-
项目类别:
-
资助金额:$25.56万
-
财政年份:2006
-
负责人:Joseph P Balthasar
-
依托单位:
FcRn Inhibitors for Antibody-Mediated Immune Conditions
-
批准号:6891084
-
项目类别:
-
资助金额:$34.49万
-
财政年份:2004
-
负责人:Joseph P Balthasar
-
依托单位:
FcRn Inhibitors for Antibody-Mediated Immune Conditions
-
批准号:6806773
-
项目类别:
-
资助金额:$34.49万
-
财政年份:2004
-
负责人:Joseph P Balthasar
-
依托单位:
FcRn Inhibitors for Antibody-Mediated Immune Conditions
-
批准号:7052902
-
项目类别:
-
资助金额:$33.68万
-
财政年份:2004
-
负责人:Joseph P Balthasar
-
依托单位:
FcRn Inhibitors for Antibody-Mediated Immune Conditions
-
批准号:7224222
-
项目类别:
-
资助金额:$32.7万
-
财政年份:2004
-
负责人:Joseph P Balthasar
-
依托单位:
Pharmacology and Bioengineering of New Treatment of ITP
-
批准号:7848331
-
项目类别:
-
资助金额:$35.32万
-
财政年份:2001
-
负责人:Joseph P Balthasar
-
依托单位:
Pharmacology and bioengineering of new treatments of ITP
-
批准号:6321765
-
项目类别:
-
资助金额:$28.26万
-
财政年份:2001
-
负责人:Joseph P Balthasar
-
依托单位:
Pharmacology and bioengineering of new treatments of ITP
-
批准号:6721337
-
项目类别:
-
资助金额:$22.74万
-
财政年份:2001
-
负责人:Joseph P Balthasar
-
依托单位:
Pharmacology and Bioengineering of New Treatment of ITP
-
批准号:7629755
-
项目类别:
-
资助金额:$35.32万
-
财政年份:2001
-
负责人:Joseph P Balthasar
-
依托单位:
Pharmacology and bioengineering of new treatments of ITP
-
批准号:6638775
-
项目类别:
-
资助金额:$26.81万
-
财政年份:2001
-
负责人:Joseph P Balthasar
-
依托单位:
海外基金